1. Catalog
  2. LQCL2609 - CMLE - Caplacizumab: The Cause Behind D ...
LQCL2609 - CMLE - Caplacizumab: The Cause Behind Delayed ADAMTS13 Activity Normalization in Thrombotic Thrombocytopenic Purpura (TTP)
Course Description

LabQ 2026 Clinical Laboratory: Hematology 
 
Faculty/Authors

Eric A. Walradth, MA, MLS(ASCP)CM SHCM 
Natalie Hartigan, DO
Hematology Oncology Associates of Central New York 
East Syracuse, New York 

CMLE Credit: 2.0

Estimated Completion Time: 2 hour

Format: Online Educational Activity and Post Exam

Instructions

To claim CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Course to view an overview of the modules in this course.
  3. Click Access to begin the course.
  4. Review the Educational Activity.
  5. Complete and submit the Post Exam.
  6. Submit the course Evaluation to register your credit.

Faculty Disclosures​
The faculty have no relevant financial relationships with commercial interests to disclose.

Technical Considerations

Release Date: 3/31/2026 
Review Date:
Expiration Date: 12/31/2028  

Course Objectives
Following completion of this activity, you will be able to

  • discuss the clinical feature and diagnostic criteria of thrombotic thrombocytopenic purpura (TTP); 

  • recognize the role of a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency in the pathophysiology of TTP and its significance in diagnosis, treatment, and monitoring; 

  • describe the mechanism of action and clinical use of caplacizumab in the management of TTP; 

  • discuss the delayed normalization of ADAMTS13 activity in patients treated with caplacizumab; and 

  • discuss the implications of delayed ADAMTS13 normalization on long-term patient outcomes. 

Summary
Availability:
On-Demand
Credit Offered:
2 CMLE Credits
Powered By